recombinant methionyl human leptin
GPTKB entity
Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
gptkb:protein |
| gptkbp:administeredBy |
subcutaneous injection
|
| gptkbp:approvedBy |
gptkb:FDA
2014 |
| gptkbp:brand |
gptkb:Myalept
|
| gptkbp:contraindication |
patients with general obesity
|
| gptkbp:genericName |
gptkb:metreleptin
|
| gptkbp:hasMolecularFormula |
C707H1132N194O218S7
|
| https://www.w3.org/2000/01/rdf-schema#label |
recombinant methionyl human leptin
|
| gptkbp:indication |
gptkb:congenital_generalized_lipodystrophy
acquired generalized lipodystrophy |
| gptkbp:marketedAs |
Amryt Pharma
|
| gptkbp:mechanismOfAction |
leptin receptor agonist
|
| gptkbp:producedBy |
recombinant DNA technology
|
| gptkbp:sequenceSimilarity |
human leptin
|
| gptkbp:sideEffect |
gptkb:hypoglycemia
leukemia allergic reactions |
| gptkbp:SIM |
human leptin
|
| gptkbp:usedFor |
treatment of lipodystrophy
|
| gptkbp:bfsParent |
gptkb:metreleptin
|
| gptkbp:bfsLayer |
8
|